Sino Biological - 官方網站

Anti-DcR2/TRAIL R4 Magnetic Beads Immunoprecipitation (IP) Kit


Anti-DcR2/TRAIL R4 Magnetic Beads-IP Kit Product Components

Components Storage
Anti-DcR2/TRAIL R4 Magnetic Beads1,3 2-8℃ for 12 months
NP40 Cell Lysis Buffer2 -20℃ for 12 months
Alkaline Elution Buffer 2-8℃ for 12 months
Acidity Elution Buffer 2-8℃ for 12 months
Neutralization Buffer 2-8℃ for 12 months

【1】The IP KIT contains anti-DcR2/TRAIL R4 magnetic Beads (2 mg/mL) in phosphate buffered saline (PBS, pH 7.4) with sodium azide (0.1%).

【2】Using NP-40 cell lysate buffer in the kit is required,otherwise,the magnetic beads may be precipitated.

【3】Shipping: Magnetic Beads kits are shipped at ambient temperature in which magnetic beads are provided in liquid buffer.

Anti-DcR2/TRAIL R4 Magnetic Beads-IP Kit Product Description

The Anti-DcR2/TRAIL R4 magnetic Beads, conjugated with Anti-DcR2/TRAIL R4 antibody, are used for immuneprecipitation (IP) of DcR2/TRAIL R4 proteins which expressed in vitro expression systems. For IP, the beads are added to a sample containing DcR2/TRAIL R4 proteins to form a bead-protein complex. The complex is removed from the solution manually using a magnetic separator. The bound DcR2/TRAIL R4 proteins are dissociated from the magnetic beads using an elution buffer.

Anti-DcR2/TRAIL R4 Magnetic Beads-IP Kit Antibody Information

Anti-DcR2/TRAIL R4 Antibody(10413-T60)
Recombinant Human TRAIL R4 / CD264 / TNFRSF10D protein (Catalog#10413-H08H)
Species Reactivity
Human TRAIL R4 / CD264 / TNFRSF10D
Polyclonal Human Rabbit IgG
Produced in rabbits immunized with purified, recombinant Human TRAIL R4 / CD264 / TNFRSF10D (rh TRAIL R4 / CD264 / TNFRSF10D; Catalog#10413-H08H; NP_003831.2; Met1-His211). TRAIL R4 / CD264 / TNFRSF10D specific IgG was purified by Human TRAIL R4 / CD264 / TNFRSF10D affinity chromatography.
Immunoprecipitation (IP), Minimum Protein Purification

Anti-DcR2/TRAIL R4 Magnetic Beads Immunoprecipitation (IP) Kit: Alternative Names

Anti-CD264ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-DCR2ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-TRAIL-R4ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-TRAILR4ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-TRUNDDALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit

DcR2/TRAIL R4 Background Information

Tumor necrosis factor receptor superfamily member 1D (TNFRSF1D), also known as TNF-related apoptosis-inducing ligand receptor 4 (TRAIL R4), CD264, and Decoy receptor 2, is a member of the TNF-receptor superfamily. This receptor contains an extracellular TRAIL-binding domain, a transmembrane domain, and a truncated cytoplamic death domain. This receptor does not induce apoptosis, and has been shown to play an inhibitory role in TRAIL-induced cell apoptosis. TRAIL R4/CD264/TNFRSF1D is widely expressed, in particular in fetal kidney, lung and liver, and in adult testis and liver. TRAIL R4/CD264/TNFRSF1D is also expressed in peripheral blood leukocytes, colon and small intestine, ovary, prostate, thymus, spleen, pancreas, kidney, lung, placenta and heart. The signaling capacity of TRAIL R4 is similar to that of TRAIL R1 and TRAIL R2 with respect to NF-κB activation, but differs in its inability to induce apoptosis. TRAIL R4 retains a C-terminal element containing one third of a consensus death domain motif. Transient overexpression of TRAIL R4 in cells normally sensitive to TRAIL-mediated killing confers complete protection, suggesting that one function of TRAIL R4 may be inhibition of TRAIL cytotoxicity.
Full Name
tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain
  • Degli-Esposti MA, et al. (1997) The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 7(6): 813-20.
  • Meng RD, et al. (2000) The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol Ther. 1(2): 130-44.
  • Bouralexis S, et al. (2003) Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer. 89(1): 206-14.
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait